CURE OM Global Science Meeting Recap

Creating a Shared Vision of Progress and Hope

Date of the meeting: November 6, 2023

Hosted by the Melanoma Research Foundation

The recent Cure OM Global Science Meeting held in Philadelphia aimed to foster a shared vision of progress and hope in the fight against ocular/uveal melanoma. The event brought together researchers, clinicians, industry partners, and patients to discuss advancements, clinical trials, and collaborative efforts. The mission, as emphasized by the Melanoma Research Foundation, is to eradicate melanoma through accelerated research, education, and advocacy.

This blog article summarizes some of the meeting’s highlights.

Navigate to Topics


Dramatic Evolution in Research Landscape

  • Reflecting on the past decade, participants noted a significant shift in the ocular melanoma research landscape.
  • In 2013, industry partners didn’t participate actively in the discussion and the focus was on understanding the unique characteristics of uveal melanoma, distinct from cutaneous melanoma.
  • In 2023, the meeting showcased substantial progress with seven industry partners actively engaging in discussions, covering primary eye treatment, genetic prognostics, metastatic disease treatments and adjuvant and neo-adjuvant therapies.

Industry Partner Presentations

Aura provided updates on AU-011 (Bel-Sar), a virus-like particle conjugated with a light activated cytotoxin which aims to kill the tumor. It is either injected suprachoroidally or intravitreally and is light-activated. They presented some positive data showing the safety and efficacy giving us hope that perhaps this could be a new primary treatment that could treat primary uveal melanoma while sparing patients from dealing with the fallout from radiation-induced retinopathy. Bel-Sar will hopefully be moving into a phase three clinical trial.

Delcath discussed Hepzato, a recently FDA-approved liver-directed therapy which is set to be commercially available in early 2024.

Ideaya reported promising data in the Phase 1/2 trial of darovasertib and crizotinib, with pivotal trials now open at multiple sites in the US and abroad. Neoadjuvant and adjuvant trials will also be opening worldwide.

Immunocore presented on tebentafusp or Kimmtrak, the first FDA approved therapy for metastatic uveal melanoma. It is now widely available in the US and abroad. And there are some ongoing trials looking at other targets.

Replimune is looking to open a clinical trial in the uveal melanoma space. They are working on an intralesional (direct injection into the tumor) modified virus. It is a herpes virus that is modified with something called GM-CSF and other immune tweaks to help the immune system recognize the cancer. In a trial, metastatic uveal melanoma patients were given either just this injection or the injection in combination with nivolumab and the response rates were upwards of 28.6% with a disease control rate of 57.1%. There is hope that this clinical trial will be available to patients soon.

TriSalus presented on the ongoing Perio-1 clinical trial. This is an intra-hepatic artery delivery of an immune stimulant via a special catheter in combination with immune checkpoint inhibitors that are given peripherally.

Discussion Points

A key emphasis was placed on the growing interest and involvement of various companies in developing treatments for ocular/uveal melanoma. While this is a positive trend, speakers highlighted the need for collaboration to avoid competition between trials and ensure inclusivity. Physicians don’t want patients to feel that if they start one clinical trial, they won’t be able to go on another. Suggestions included making inclusion and exclusion criteria less restrictive, ensuring trials are accessible across different regions and supporting patients so that lack of access to clinical trials is not a reason to not participate.

Liver-Directed Therapy – Pros and Cons

The discussion then turned to liver-directed therapy, a crucial treatment approach for uveal melanoma. Dr. Orloff underscored the importance of understanding the pros and cons of liver-directed therapy, systemic therapy, and combination therapy. These considerations are crucial for patients facing decisions about the most suitable treatment path.

1. Liver-Directed Therapy:
  • In MUM, liver metastases are leading cause of death
  • Various liver directed treatments can be very effective at controlling hepatic metastases
  • Often well tolerated with limited side effects experienced between treatments
  • Some patients only require limited treatments with long treatment free intervals
  • Not restricted to any one population
  • Have one FDA approved LDT option (PHP)
  • MUM by definition is a systemic disease and extrahepatic disease can develop and lead to morbidity and rarely mortality
  • Requires institutional expertise
  • Patients may need to travel further for treatment
  • Some liver directed treatments require more extensive resources
  • Limited randomized trial data (comparing LDT or to systemic treatments)
2. Systemic Therapy:
  • Treatment of systemic disease (treats the whole body)
  • Tebentafusp is available and has an overall survival benefit and good side effect profile
  • Darovasertib + Crizotinib is also an option with a decent objective response rate (ORR) and disease control rate (DCR)
  • Tebentafusp is HLA restricted
  • It needs to be injected weekly
  • It has a low response rate and has a high rate of immune-related adverse event
  • It may not shrink tumours up-front
  • Often systemic trials are restricted to line of therapy
3. Combination Therapy:
  • Potential to control both hepatic and systemic metastasis
  • Opportunities for debulking tumors before systemic therapy
  • Synergy of liver directed treatment and systemic treatment especially when using systemic immunotherapy
  • Optimal combinations and sequences are unknown
  • Toxicities of both therapies need to be managed

Data Highlights and Proposed Studies


TriSalus presented data as a late-breaking abstract at the Society for Immunotherapy of Cancer (SITC) annual meeting. They are investigating their special catheter that allows infusion of SD-101 infusion in combination with immunotherapy. There have been multiple cohorts, and the results so far show a 58% disease control rate (DCR) across all SD-101 doses and an 81% DCR at two milligrams. Optimizing dosage is a focus, as higher doses may not necessarily be more effective. Preliminary overall survival signals are encouraging.

Percutaneous Hepatic Perfusion (PHP)

PHP is a catheter system facilitating closed-circuit liver perfusion with melphalan. Results from the focus trial, presented in 2022 at ASCO, demonstrated significant improvements in overall response and disease control compared to alternative care arms. Side effects, primarily related to bone marrow suppression, were noted.

Combination Trial Designs

Ongoing trials show promise in combining hepatic perfusion with immune checkpoint inhibitors.

  • The Scandium II trial compared hepatic perfusion (IHP) followed by immune checkpoint inhibitors (ICI), with ICI followed by IHP followed by more ICI. The Scandium III trial compared ICI alone with PHP followed by ICI.
  • Another trial presented by Dr. Orloff explored combining tebentafusp with liver-directed therapy. For lower volume disease, the design involves administering tebentafusp upfront, followed by liver-directed therapy. For higher volume disease, the design involves chemoembolization first, followed by tebentafusp.

Adjuvant and Neo-Adjuvant Clinical Trials

Three new trials will be opening soon in the adjuvant/neo-adjuvant space:

  • Quizinostat (University of Miami)
  • Neoadjuvant/Adjuvant Darovasertib
  • ATOM: Adjuvant Tebentafusp Ocular Melanoma

Tebentafusp in Practice

Dr. Butler, Dr. Sullivan and Dr. Seedor all presented on tebentafusp in practice. Tebentafusp is a bispecific molecule that brings T-cells to the tumour and have been showed to offer significant survival benefits. The challenge lies in translating clinical trial success to real-world scenarios, where patients might have more advanced disease.

Dr. Seedor shared case vignettes featuring patients with a substantial disease burden. These patients showed potential benefits from tebentafusp but Dr. Seedor suggested that stabilizing patients before initiating tebentafusp might be necessary for optimal outcomes.

Dr. Butler presented on the situation in Canada, where initial access to the drug was previously restricted to two centres, but has now expanded nationwide, enabling a diverse group of patients to undergo tebentafusp treatment. In a real-world grouping of patients, it was observed that stabilization or positive responses to tebentafusp were linked to improved outcomes, aligning with findings from clinical trials and showing that a variety of patients are experiencing benefits from tebentafusp.

Dr. Sullivan presented innovative data addressing the challenge of assessing tebentafusp’s impact on cancer. While the drug may not necessarily shrink tumours, it slows down their growth. Traditionally, oncologists rely on tumour shrinkage to gauge treatment efficacy. Dr. Sullivan discussed findings suggesting that even in cases of disease progression on imaging, a decrease in circulating tumour DNA correlates with a more favourable response to therapy. However, the specific assay used in the study isn’t commercially available. Dr. Sullivan found that there are several ways to analyze circulating tumour DNA and cells in the blood fraction and that one of them might be better suited to patients with uveal melanoma, suggesting that even patients who are on standard of care treatment may benefit from clinical trials that use this biomarker as a way to follow patients.

Systemic Therapies Highlights

Several presentations focused on systemic therapies.

Dr. Moser shared insights into emerging therapies:

  • Roginolisib – PI3Kδ inhibitors are showing promising results in patients and in animals
  • Radioligand therapy – A novel approach to targeting tumors using a molecule that brings radiation particles directly to the tumour to target tumour cells.
  • TCR Therapy – Promising trials are trying to target tumors with cell therapies. There are actually several different studies looking at TCR based therapies, CAR T-cell based therapies as well as tumor infiltrating lymphocyte therapies are being studied across the world to determine the best approach for patients.

Dr. Hamid explored byspecific antibodies in OM:

  • He highlighted the three-year survival rate for tebentafusp, which showed a consistent benefit in terms of overall survival. Unfortunately, not enough patients are doing really well five years later, but certainly, they’re doing better than they were on the investigator’s choice protocol.
  • Immunocore has a new agent called F106C that targets PRAME, which is an antigen expressed highly in uveal melanoma but also in other types of cancers. They’ve seen a high percentage of response in patients with uveal melanoma as well as skin tumours. And there are several follow up trials beyond the initial phase one to look at the role of this study in patients with uveal melanoma, cutaneous melanoma, as well as other tumours in the future.
  • Various different types of immune cells are being investigated for cancer treatment:
    • Lymphocyte cells that are allogeneic (cells that come from one person and are used in another person to fight the cancer)
    • CAR T-cell
    • Bispecific agents brought into a cell and infused as a therapy
    • Human mesenchymal stromal cells

Dr. Butler presented on Protein Kinase C Inhibition. He covered the promising results of darovasertib in combination with crizotinib for uveal melanoma, presenting a high response rate, even in patients with significant disease burdens. The phase one study, having transitioned to phase two/phase three, is now comparing darovasertib and crizotinib to immunotherapy or investigator choice in the first-line setting. The study aims to provide insights into the therapy’s duration, side effects, and optimal administration strategies across multiple centres. However, challenges remain, such as determining the sequencing of therapies, determining which patients should get the drug right away and which patients should be treated later on, and engaging with pharmaceutical companies to ensure patients have access to various treatment lines.

Dr. Khan reviewed data on immunotherapy with checkpoint inhibitors, pointing out that, while there is a higher response rate with combination immunotherapy, there are many more side effects with combination immunotherapy compared to single agent anti PD-1 therapy. Studies that compared ipilimumab + nivolumab versus nivolumab or pembrolizumab alone showed that the overall survival rate in these non-concurrent clinical trials are not that different. The response rate is a bit higher for combination versus single agent but there is no significant difference in overall survival.

One study looked at the LAG-3 combination of nivolumab and relatlimab and found that the response rate was higher than for a single agent, but a little bit lower than combination in that study. It may be an option for patients that want a higher response rate with less side effects.

Patient-Powered VISION Registry

Sara Selig introduced the VISION platform, a patient-powered real-world registry. With over 400 registered patients, the platform aims to collect data on diagnosis, barriers to treatment, and patient priorities. This valuable information aids in understanding the patient experience and advocating for improved resources and access.

In conclusion, the CURE OM Science Meeting showcased a vibrant landscape of advancements in ocular melanoma treatment. From neoadjuvant trials to real-world applications and promising biomarkers, the meeting underlined the collaborative efforts driving progress. As patients, advocates, and researchers continue to navigate this journey, the collective commitment to advancing knowledge and accessibility remains a beacon of hope.

Get Support

Save Your Skin Foundation wishes to bring hope and support to all those touched by melanoma, non-melanoma skin cancers, or ocular melanoma – whether they are newly diagnosed, currently undergoing treatment, in remission or referred to as “NED” (no evidence of disease).


We are here to help. Call us at 1-800-460-5832 or email

Learn about our other resources for ocular melanoma patients:

Ocumel Canada

Ocumel Canada, an initiative of Save Your Skin Foundation, was formed to increase awareness, advance treatment options, and build a supportive community for those diagnosed with primary and/or metastatic ocular melanoma (OM).

About Ocular and Uveal Melanoma

This page contains lots of information about ocular/uveal melanoma and resources for patients.

Read more

Is Skin Cancer Curable?

Skin cancer is a prevalent form of cancer that affects millions of people worldwide. In Canada, about 80,000 people are diagnosed with skin cancer each year.[1] Skin cancer encompasses various types, with the most common being basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. If you or someone you know has been diagnosed with skin cancer, you may be wondering “is skin cancer curable?” The outlook for individuals with skin cancer depends on several factors, including early detection, type, stage, and treatment. Let’s explore what the experts have to say.


Early Detection is Key

According to the Cleveland Clinic, nearly all skin cancers can be cured if they’re treated before they have a chance to spread. This emphasizes the crucial role of early detection. The earlier skin cancer is found and removed, the better the chances of a full recovery. It’s essential to schedule regular check-ups with a dermatologist to ensure that any potential issues are identified promptly. If you notice something unusual on your skin, don’t hesitate to contact your doctor.


Types of Skin Cancer

As noted by the Cancer Research UK, different types of skin cancer have varying prognoses:


Basal cell carcinoma (BCC)

BCC is highly curable, with an extremely low likelihood of spreading to other parts of the body. Most cases can be treated effectively by removing the cancerous tissue along with a small margin of surrounding healthy skin.


Squamous Cell Carcinoma (SCC)

SCC is also typically curable, with a high success rate in treatment. In some instances where SCC has spread to lymph nodes or other parts of the body, it may still be curable through appropriate treatment such as surgery, radiation therapy, targeted therapy, or cryotherapy.[2]



Early stage melanoma is often curable through surgery.[3] Among the surgical techniques available for melanoma, wide excision is commonly recommended. This procedure involves the complete removal of the cancerous tissue. More advanced melanoma will often require additional forms of treatment, such a s lymph node dissections, immunotherapy and targeted therapy.

Prognostic Factors

The prognosis for non-melanoma skin cancers is generally excellent, but various factors can influence the outcome, as explained by the Canadian Cancer Society. These factors include:

Location: Skin cancer on certain areas, such as around the eyes, nose, lips, ears, scalp, fingers, toes, and genitals, may have a higher risk of recurrence or metastasis.

Size and Depth: Larger tumors and those that have grown deep into the skin are more likely to come back.

Recurrence: Skin cancer that returns after treatment may have a less favorable prognosis.

Type or Subtype: Some subtypes of BCC and SCC tend to grow more quickly and have different outcomes.

Immunosuppression: Weakened immune systems can impact the prognosis.

Stage: The stage at diagnosis is a significant determinant of prognosis.

Outlook for Skin Cancer In general, the outlook for skin cancer is positive. The 5-year survival rate for melanoma is 99% if detected and treated before it spreads to the lymph nodes, according to the American Academy of Dermatology. For BCC and SCC, the outlook is favorable, especially when diagnosed early. However, as skin cancer advances, the prognosis may vary. In conclusion, most skin cancers are curable, especially when detected and treated in their early stages. Early detection, regular check-ups with a dermatologist, and prompt treatment are essential in ensuring a positive outcome. While skin cancer can be a serious diagnosis, advances in medical treatments offer hope and optimism for those affected by this condition. If you have concerns about your specific case, consult with your healthcare provider for personalized guidance on your prognosis and treatment options.

Is Skin Cancer Curable?

In general, the outlook for skin cancer is positive. The 5-year survival rate for melanoma is 99% if detected and treated before it spreads to the lymph nodes, according to the American Academy of Dermatology. For BCC and SCC, the outlook is favorable, especially when diagnosed early. However, as skin cancer advances, the prognosis may vary.

In conclusion, most skin cancers are curable, especially when detected and treated in their early stages. Early detection, regular check-ups with a dermatologist, and prompt treatment are essential in ensuring a positive outcome. While skin cancer can be a serious diagnosis, advances in medical treatments offer hope and optimism for those affected by this condition.

Please remember that the statistics and opinions cited on this page are general, and do not apply to every person’s experience of skin cancer. And if you have concerns about your specific case, consult with your healthcare provider for personalized guidance on your prognosis and treatment options.

Get Support

Save Your Skin Foundation wishes to bring hope and support to all those touched by melanoma, non-melanoma skin cancers, or ocular melanoma – whether they are newly diagnosed, currently undergoing treatment, in remission or referred to as “NED” (no evidence of disease).


We are here to help. Call us at 1-800-460-5832 or email

Learn More About Immunotherapy

Immunotherapy is a drug treatment that uses the human body’s own immune system to fight cancer.  It may be administered to patients intravenously in the Chemotherapy Unit of the hospital, but it is not the same as chemotherapy.

Learn More About Targeted Therapy

Targeted therapy drugs are designed to specifically target cancer cells. For melanoma, these drugs target the activity of a specific or unique feature of melanoma cancer cells.

Learn More About Clinical Trials

New treatments are tested in clinical trials before they are approved for general use. There are safeguards in place to ensure clinical trials are as safe as possible and meet medical ethical standards. Participating in a trial can be a way to have access to potentially helpful new therapies you couldn’t get otherwise.

[1] “Skin Cancer.” Canadian Skin Cancer Foundation, Accessed 9 Oct. 2023.

[2] “Is Skin Cancer Curable.” Medical News Today, Accessed 9 Oct. 2023.

[3] “Melanoma Overview.” Skin Cancer Foundation, Accessed 9 Oct. 2023.

Read more

Move for Melanoma 2023 – It’s a Wrap

A tremendous THANK YOU to all of our incredibly dedicated participants and generous donors!

50 participants and 14 teams across Canada took part in Move for Melanoma this year! We have been so moved and inspired by this incredible community of patients, families, and friends.

After the success of last year, we once again set ourselves an ambitious goal of raising $75,000. With your help, we ended up reaching our goal once again this year!

Video wrap up

To wrap up this monumental weekend, we’ve created the Recap Video below. We hope you will take a few moments to watch it as we pay tribute to our incredible participants, donors and sponsors across Canada. You can also view our 2023 PSA with J.T. Miller from the Vancouver Canucks!

We’d also like to highlight the three fundraising teams that raised the most this year.

Team Ocumel Canada

Based in Victoria, BC, Team Captain Nigel Deacon ran a marathon distance to inspire others to donate to this worthy cause. Together with his fellow team members, they raised an incredible $12,777 for ocular melanoma patients.

Check out his team page here.

Scots across the Rockies

Based in Powel River, BC, Team Captain Taylor Tomko created a family donation page in hopes of inspiring others to donate to this worthy cause. Together with her fellow team members, they raised an incredible $9,704 for melanoma patients.

Check out her team page here.

Helen’s Freewheelers’s

Based in Nanaimo, BC, Team Helen’s Freewheelers raised funds in honour of Helen’s courageous battle against metastatic Basal Cell Carcinoma. She’s now undergoing immunotherapy on Vancouver Island and exploring more advanced treatment options and clinical drug trials. The team raised $6,000

Check out their team page here.

Finally, we’d like to acknowledge the many businesses that stepped up to support our event this year. Please show them your support!

Read more

8th Annual Patients Redefining the Future of Health Care in Canada Summit

Are you ready to be a part of a groundbreaking event that brings together patients, caregivers, and healthcare stakeholders from across the country? The 8th Annual Patients Redefining the Future of Health Care in Canada Summit is here! Mark your calendars for the week of Nov. 13 and get ready to be inspired, educated, and empowered to shape the future of healthcare in Canada.

This annual patient education and awareness Summit is a collaborative effort between two organizations – Save Your Skin Foundation and the Canadian Psoriasis Network, in conjunction with an Indigenous volunteer from Kiyasiw Consulting. Together, they are committed to elevating the voices of patients and caregivers, amplifying their experiences, and addressing long-standing systemic issues related to equity and oppression in our health systems.

What to Expect:

The Summit promises an exciting lineup of community leaders, advocates, and experts who will engage in insightful discussions about the challenges faced in meeting people where they are at, highlighting Indigenous health needs, and exploring opportunities to modernize healthcare to meet the needs of all Canadians.

The Schedule:

  1. Nov. 13 – Challenges to Meeting People Where They’re At
    • Time: 11 AM – 4 PM EST
  2. Nov. 15 – Highlighting Indigenous Health Needs
    • Time: 12 PM – 4 PM EST
  3. Nov. 16 – Opportunities to Modernize Health Care to Meet the Needs of All
    • Time: 12 PM – 4 PM EST
  4. Nov. 17 – Patient Planning Session (restricted to patients/caregivers and related groups)
    • Time: 12 PM – 1:30 PM EST

Why Attend:

This summit is a unique opportunity to engage in open dialogue, gain valuable insights, and contribute to the transformation of the Canadian healthcare system. It’s a chance for patients, caregivers, and healthcare stakeholders to come together, share their stories, and collectively find ways to create a more inclusive and patient-centric healthcare environment.

By attending the summit, you will:

  1. Learn about the challenges faced by patients and caregivers in accessing healthcare services.
  2. Understand the unique healthcare needs of Indigenous communities and how to address them effectively.
  3. Discover opportunities to modernize healthcare and make it more accessible and inclusive.
  4. Connect with like-minded individuals and organizations dedicated to making a positive impact on Canadian healthcare.

Check out some of our content from last year’s Summit!

Ready to Register?

We’re thrilled to have you join us at the 8th Annual Patients Redefining the Future of Health Care in Canada Summit. Registration is now open, and you can secure your spot by clicking the link here!

Don’t miss out on this exceptional opportunity to be a part of a movement that aims to reshape the future of healthcare in Canada. Let’s work together to create a healthcare system that meets the needs of all patients, regardless of their background or circumstances.

We look forward to seeing you at the Summit!

Read more

Hair Heroes Challenge

We are happy to announce that Save Your Skin Foundation has partnered with the Ontario Professional Hairstylist Association to launch the Hair Heroes Challenge!

The Challenge calls on all hairstylists and hair schools across Canada to show off  their skills and make a difference in the fight against skin cancer with Sty-Lives. This social media campaign in English and French aims to showcase just how simple and effortless skin cancer scalp checks can be. 

Participating is easy, and participants have two options:

Options 1: Shoot a captivating video (60 seconds or less) where they demonstrate their hairstyling prowess while performing a skin cancer check on their client.

Option 2: Capture the transformation with a before and after photo of their client’s hair, following a thorough check or styling session.

We had the pleasure of being interviewed by OPHA about the Challenge. Watch the video to learn more.

Want to participate? Don’t forget to include our official hashtags, #HairHeroes & #Sty-lives2023, mention Sty-Lives, and let your imagination run wild! The SYSF team will be on the lookout for the most imaginative video that not only promotes Sty-Lives, but also showcases the importance of skin cancer checks. You’ll stand a chance to win an amazing prize that will leave you jumping for joy! So, grab those scissors, unleash your imagination, and get ready to win big with Sty-Lives!

This challenge is running through all social media platforms such as TikTok, Facebook, Twitter & Instagram. Don’t forget to tag us! 

Read more

Move for Melanoma 2023

Move for Melanoma is an activity challenge that takes place across Canada. The goal of the event is to bring awareness to melanoma, non-melanoma skin cancer and ocular melanoma, while raising funds to support patients affected with these diseases when they need it most.

This year, the event will take place on September 22-24th, 2023. As always, participants will be able to choose a physical challenge of their choice to complete on the weekend of the event. Participants will form teams and, together with their friends and family, try to reach their personal fundraising goals.

To facilitate the whole thing, again this year, we will be using a custom website that allows people to register, donate, solicit donations, track progress and promote the event all in one place. The website also includes many resources for participants to help them get ready, and a Q&A page for more information.

If you’re interested in joining us, please visit Move for Melanoma 2023 and register now.


Save Your Skin Foundation is the only organization in Canada that supports skin cancer patients financially when they need it most. All the money raised through your donations goes directly to patients in the form of cab fares, treatment costs, flights, accommodation and other necessary but costly expenses incurred while receiving treatment.

Whether you’re a survivor who wants to bring hope to newly diagnosed patients, the family member or friend of a patient who wants to send a powerful message of solidarity, or a patient who wants to help change the face of cancer for ever, we invite you to take a stand against melanoma and to move with us this September!

Hand in hand, we fight melanoma together!

Read more

A Historic Milestone: Manitoba Proclaims May as the First Provincial Melanoma and Skin Cancer Awareness Month

May is Melanoma and Skin Cancer Awareness Month, and this year marks a significant achievement as the Province of Manitoba joins the cause by proclaiming May 2023 as the first-ever Provincial Melanoma and Skin Cancer Awareness Month. Save Your Skin Foundation and Ocumel Canada are at the forefront of this initiative, leading local, national, and international campaigns to raise awareness about the importance of prevention and early detection of skin cancers.

Discover a comprehensive list of initiatives for Melanoma Skin Cancer Month and Ocular Melanoma awareness HERE.

For the fourth consecutive year, Save Your Skin Foundation’s proclamation initiative has invited Canadian municipalities to take a firm stance against skin cancer and educate their communities about sun safety through mayoral proclamations. As of May 25, 2023, an impressive 43 municipalities have committed to declaring May 2023 as ‘Melanoma and Skin Cancer Awareness Month.’ Check the list HERE to see if your city is among them.

The Honourable Audrey Gordon, on May 25th, 2023, officially proclaimed the month of May 2023 as Melanoma and Skin Awareness Month in Manitoba. This remarkable step underscores the government’s recognition of the importance of efforts aimed at reducing the incidence of skin cancer.

"The Save Your Skin Foundation's tireless work and initiatives in raising awareness about non-melanoma skin cancers, melanoma, and ocular melanoma through nationwide education, advocacy, and awareness campaigns are truly commendable. Our government acknowledges the significance of efforts to reduce the incidence of skin cancer. I extend my best wishes to Save Your Skin Foundation for the success of their planned events during Melanoma and Skin Cancer Awareness Month."

Hon. Audrey Gordon

We are immensely grateful to the Honourable Audrey Gordon for her support and belief in the importance of sun safety.

Additionally, members of our SYSF team have had the privilege of presenting to the Mayors and Councils of several municipalities nationwide, sharing their personal experiences as patients and spreading the crucial message of sun safety and early detection of skin cancer.

Read more

SYSF 2023 Sunscreen Dispenser Pilot Launches June 1st!

On June 1st, 2023, SYSF is launching 30 public sunscreen dispensers across five new Canadian municipalities. This is in addition to the 10 dispensers across five municipalities SYSF collaborated on in 2022 with medical student siblings Samuel and Karen Farag.

The bright yellow dispensers are automatic and touchless, and provide free, Health Canada approved SPF 30 sunscreen for anyone who needs it. The sunscreen is zinc oxide based, free from chemical sunscreen filters, common allergens and toxic ingredients including oxybenzone, avobenzone, retinyl palminate, PEG, perfume, and sodium lauryl sulphate. To learn more about the SYSF sunscreen dispenser initiative, see our Sunscreen Dispensers page.

Remember that no tan is a safe tan. While you are enjoying Summer activities, try to limit your time in direct sunlight between 11am and 3pm; seek shade; and cover up by wearing UV-protective clothing, such as long pants, long sleeves, and a hat. Use SPF 30+ broad-spectrum sunscreen (which protects against both UVA and UVB rays), which you should apply 20 minutes before sun exposure and reapply every two hours or directly after swimming. Don’t forget SPF for your lips and your sunglasses!


Here is the complete list of dispenser locations:

Grand Bay-Westfield, NB: two dispensers at Brundage Point River Centre and Tail Whip Park/Splash Pad

Lake Cowichan, BC: six dispensers across Lake Cowichan township and Gordon Bay Provincial Park

New Brunswick Fairs & Exhibitions Association: four dispensers to be at 13 fairs and events across New Brunswick

New Westminster, BC: four dispensers across Moody Outdoor Pool, Hume Outdoor Pool, Grimston Park Wading Pool

Penticton, BC: five dispensers across Skaha Meadows Golf Course, Penticton & Wine Country Chamber of Commerce, Penticton Speedway, Barefoot Mini Mart, Travel Penticton

Richmond, BC: four dispensers across South Arm Outdoor Pool, Steveston Outdoor Pool, Watermania

Riverview, NB: two dispensers each in Lion’s Community Park and at events around the city

Summerside, PEI: four dispensers, one each at Summerside Turf Field, Leger Park, Summerside Boardwalk, and one to be used at public events

Vancouver, BC: one dispenser to be installed at the YMCA hotel

Westlock, AB: four dispensers across Westlock skateboard park, Westlock tennis courts, and the Westlock baseball diamonds

Read more

Meet The New Canadian UPF 50+ Protective Beachwear Line – KRABĒO

About The Founder of KRABĒO

In November 2021, I was told for the second time that I had cancer. This is not something one gets used to hearing, and at that moment I felt like another bomb went off in my life and my husband’s.

This diagnoses was followed by a series of tests that started from the end of November up to the 2021 holiday season. The reason for this was to gain an understanding of this possible recurrence all these years later.

Over 17 years ago, I had a beauty mark on my back that itched like a mosquito bite, which I thought was odd. That was back when tanning salons were a trend and I would visit them several times a week to do something about my “milky white” complexion. At this time, I felt I needed those sessions to look more “healthy”. I even had a membership at a local tanning salon! One day, just before settling in for a session, I discussed my beauty mark with the owner who urged me to get it checked out, which I did a few weeks later.

In creating KRABĒO, I find myself with peace of mind. Peace of mind for myself, my family and for you.

Marie-Ève Richard

I was 24 when it first happened and honestly, I felt I was above it until a lymph node surfaced in September 2021. It was then that I noticed a small lump in my right groin that many doctors thought was harmless, but I had a feeling that it was not benign.

I had to persist with the healthcare system to go further and do more tests in order to find out what was wrong. When you have a feeling that something is wrong, you need to advocate for yourself & ask questions. In my case, I was indeed wrong. The doctors discovered after an ultrasound that it was melanoma. This was quite a shock & a return to square one.

I hesitated to tell my story when all of this happened, even to my kids, but I would come to understand the importance of sharing one’s life experiences. No matter if it’s good or bad because doing so can help others.

My story may be your story too! It made me realize the great lack of resources and knowledge about this disease and how to adequately protect myself from the sun. It’s because of what I went through that I decided to help the people around me and the population by developing a line of UV-protective beachwear. Our beachwear is certified and recognized by the highest world standards of sun protection and it covers 98% of UVA and UVB rays. KRABĒO was born from this desire and is made entirely made in Quebec with love. Now, whenever I see my clothing worn by people from all walks of life, including children, my heart swells at the idea that I was able to do my part in the fight against this preventable cancer that has cases increasing with each passing year.

In creating KRABĒO, I find myself with peace of mind. Peace of mind for myself, my family and for you.


At KRABĒO, we believe that the sun, the water and the beach are together a source of well-being. To take full advantage of it all, one thing is essential: sun protection. We love to enjoy the sun. The benefits it brings to our lives are of course impossible to ignore. We tend, however, to forget the risks related to UV rays.

We can’t say it enough: ultraviolet rays from the sun lead to premature ageing, the appearance of skin blemishes, as well as skin cancer, which represents a full third of the most widespread cancers in the world.
For us, skin protection in all of its aspects lies at the very centre of every one of our decisions; indeed, it is our guiding principle.

Our laboratory-tested fabrics are certified UPF 50+ and block 98% of UVA and UVB rays, without any toxic products involved, neither for the skin nor for the planet.

They have been carefully chosen to meet two criteria: protecting our skin and preserving the oceans.

KRABĒO has generously offered a special 10% discount to all Save Your Skin Foundation newsletter subscribers. The code will be available in our May newsletter so hurry up and subscribe if you haven’t already!

All Collections

Children’s Collection

New Arrivals

Their dedication to the cause

KRABĒO is committed to helping others. That’s why the KRABĒO community lends its hand to those suffering from skin cancer by supporting the Save Your Skin Foundation and donating a portion of its profits to the cause!

Read more

Welcoming MorrisonRowe – A New Canadian UV Protective Clothing Brand

MorrisonRowe is an EVERYday sun protection clothing company based in Calgary, Alberta. MorrisonRowe was founded by long-time friends Cara and Tegan after Cara was diagnosed with multiple basal cell carcinomas. Her dermatologist recommended that she cover up as much as possible and wear sun protective clothing when outside. She found lots of options for the beach or sport specific activities but struggled to find casual, everyday UPF 50+ clothing. She didn’t want to look or feel like she was headed to the beach while she was out for daily activities such as going to the park with her kids, walking the dog, or sitting on a patio with friends.

Cara and Tegan could not ignore this HUGE gap in the market and the need for casual everyday UPF 50+ sun protection clothing. What started as a need, turned into a business idea and Cara and Tegan embarked on the journey to launch their own UPF 50+ sun protection clothing brand.

Prior to starting MorrisonRowe Cara worked as a registered nurse in surgical oncology and Tegan  a professional engineer. Neither had any previous fashion industry experience so it was quite a journey to build the brand from scratch.

Our mission is to make sun protection clothing part of your everyday wardrobe so you can grab something from your closet and know that no matter where the day takes you, sun protection is there. We have combined timeless style and everyday comfort with UPF 50+ protection so you don’t have to choose between looking great, feeling good, and protecting your skin.

Cara and Tegan

Cara and Tegan had some guiding principles for the brand; they wanted all of their clothes to be rated UPF 50+, they wanted to be a Canadian brand, and they wanted their clothes to be sustainably sourced and ethically made.

In terms of the actual clothing, Cara and Tegan had specific design concepts and fabric preferences. To them “everyday” means clothes that are timeless, casual and relaxed. Something that you will reach for any and EVERY day. For the fabrics, Cara and Tegan wanted natural fiber fabrics like Tencel™, hemp, and organic cotton because they offer superior breathability, feel great on your skin, and their production is generally more sustainable. This fabric preference is a definite departure from most available UPF 50+ clothing.

Finding fabrics proved to be one of the biggest challenges on the journey to launching MorrisonRowe. (Other than the pandemic and raising young children of course). Cara and Tegan searched tirelessly to find sustainable and ethically made, natural and recycled fabrics that were UPF 50+. Most fabric manufacturers Cara and Tegan contacted had minimal or no experience with UPF testing and rating, especially when it came to using natural fiber fabrics.

They knew that natural fiber fabrics with UPF 50+ ratings existed but sourcing them proved to be a challenge. They quickly learned that if they wanted to use natural fiber fabrics they would have to send them for testing and rating themselves. Fabrics were chosen based on what Cara and Tegan wanted in terms of how they feel, the composition, the garment design, and sustainability and then sent for basic UPF testing. If the result came back below UPF 50, Cara and Tegan were back to square one. This happened a few times before they found the right fabrics.

All MorrisonRowe fabrics are independently third party tested and rated at a lab in Quebec according to industry standards (ASTM D6544 and AATCC 183) to ensure every colour is UPF 50+. MorrisonRowe fabrics are all free of any chemical treatments to make them UPF 50+.  Rather, the natural characteristics of the fibers, the structure of the fabric, and the colour is what makes the fabric UPF 50+.

All MorrisonRowe clothes are designed and manufactured in Canada. Cara and Tegan have worked with a local Calgary designer, Ereau Designs, from the beginning. And manufactured solely in Calgary until recently moving manufacturing to Vancouver. They have styles for women, men, and children and are continuing to expand their catalogue.

MorrisonRowe has generously offered a special 10% discount to all Save Your Skin Foundation newsletter subscribers. The code will be available in our May newsletter so hurry up and subscribe if you haven’t already!

Women’s Collection

Men’s Collection

Junior Collection

Read more